In this study, we reasoned that Δψm-inducing effects of vandetanib and cabozantinib are due to RET inhibition and hypothesized that a low dose of selpercatinib will also increase Δψm in RET-mutated tumor cells, priming the tumor cells to MitoQ sensitivity. This evidence concerns the gene RET and neoplasm.